XYXiaojun Yuan

Xiaojun Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaojun Yuan has a total of 133 co-authors. Here are the top co-authors by number of shared publications:

  • DeeDee M. Bennett Gayle

    10 shared publications
  • Qianya Jin

    Department of Pediatric Hematology/Oncology, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

    3 shared publications
  • Jun Lu

    Department of Hematology/Oncology Children's Hospital of Soochow University Suzhou China

    2 shared publications
  • Meng-Jie Tang

    Department of Pediatric Hematology/Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Mengjie Tang

    Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Yanmin Chen

    Department of Pediatric Hematology/Oncology, Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

    2 shared publications

Latest Publications

  • Open Access

    Low‐Dose Cytarabine Plus G‐ CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study

    by Wenxin Ou, Xiaohua Zhu, Jun Lu, Hongsheng Wang, Ning Liao, Yufeng Liu, Hua Jiang, Qi An, Xiaojun Yuan, Hailong He, et al.

    This retrospective secondary analysis of the multicenter randomized CALS III‐AML18 trial evaluated the efficacy and safety of low‐dose chemotherapy (LDC) compared with standard‐dose chemotherapy (SDC) in children with M2 acute myeloid leukemia (AML‐M2). A total of 221 children were included, with 109 in the LDC arm and 112 in the SDC arm. The complete remission (CR)/CR with incomplete recovery (CRi) rates after induction I and II were 67.0% versus 70.5% ( p = 0.568) and 84.4% versus 89.3% ( p = 0.740), respectively. The 3 year overall survival (OS) rates were 81.2% ± 3.9% and 86.9% ± 3.3% in the LDC and SDC arms, respectively ( p = 0.304). The corresponding 3 year relapse‐free survival (RFS) rates were 82.0% ± 3.8% and 88.1% ± 3.1% ( p = 0.205), and the 3 year event‐free survival (EFS) rates were 62.1% ± 4.8% and 70.8% ± 4.4% ( p = 0.218). Among patients with KIT mutations, outcomes were poorer in the LDC arm than in the SDC arm, including 3 year OS (67.1% ± 8.7% vs. 91.5% ± 4.1%, p = 0.011), RFS (70.6% ± 7.8% vs. 87.5% ± 4.8%, p = 0.038), and EFS (49.2% ± 8.7% vs. 81.0% ± 5.7%, p = 0.002). Among patients who developed sepsis, grade 3–5 events were less frequent in the LDC arm than in the SDC arm (33.3% vs. 78.8%, p < 0.001). LDC was also associated with faster neutrophil and platelet recovery, lower transfusion requirements, and reduced treatment costs during induction. No statistically significant differences in remission or survival outcomes were observed between LDC and SDC, while the LDC regimen showed a lower treatment‐related burden. These findings support further evaluation of LDC as a toxicity‐sparing induction strategy in selected pediatric patients with AML‐M2. The poorer outcomes observed among patients with KIT mutations warrant caution when considering treatment de‐intensification in this subgroup.

  • Open Access

    The efficacy and safety of Huaiqihuang Granule in the treatment of childhood chronic primary immune thrombocytopenia: a multi-centre, randomized, double-blind, placebo-controlled clinical study ( )

    by Juan Han, Qiang Fu, Changda Liang, Xiaojun Yuan, Xiaoli Zhang, Wenge Hao, Yanhua Yao, Yufeng Liu, Lirong Sun, Yongjun Fang, et al.

  • Open Access

    Diffuse infantile hepatic hemangioma successfully treated with propranolol orally: a case report and literature review

    by Zengyan Li, Zhiming Wu, Youhong Dong, Xiaojun Yuan, Dongdong Zhang

    Background: Infantile hepatic hemangioma (IHH) is a common vascular, fast-growing hepatic tumor that is usually accompanied by multiple cutaneous hemangiomas. Diffuse IHH (DIHH) is a rare type of IHH that exhibits many tumors with nearly complete hepatic parenchymal replacement. At present, there is no specific standardized treatment plan for DIHH. Herein, we present the case of a 2-month-old girl with DIHH and without cutaneous hemangioma who achieved complete remission after undergoing propranolol monotherapy.Case presentation: The infant with low birth weight was presented to the pediatric department with a 2-month history of persistent vomiting and feeding difficulty. Ultrasonography and abdominal magnetic resonance imaging revealed hepatomegaly and diffused intrahepatic lesions. A computed tomography-guided percutaneous liver biopsy was performed, and the pathological examination suggested the diagnosis was DIHH. The patient exhibited remarkably response to an increasing dose of oral propranolol, from 0.5 mg/kg to 2 mg/kg every day. The intrahepatic lesions were almost completely regressed after one year of treatment and no distinct adverse reaction was observed.Conclusion: DIHH can induce life-threatening complications that require prompt interventions. Propranolol monotherapy can be an effective and safe first-line treatment strategy for DIHH.


  • Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma

    by Jiaxi Du, Xiaojun Yuan

    Patients with high-risk neuroblastoma (HR-NB) exhibit suboptimal 5-year survival rates, leading to a widespread international preference for high-intensity chemotherapeutic regimens in these children. We analyzed the incidence and risk factors for complications during induction chemotherapy in children with HR-NB and tried to assist clinicians in predicting such complications and optimizing therapeutic strategy. The clinical data of children with HR-NB admitted to our hospital from January 2007 to December 2019 were retrospectively analyzed. The incidence, characteristics, and risk factors of complications (infection, hemorrhage, and chemotherapy-related adverse reactions (CRAR)) requiring hospitalization during induction chemotherapy in these children were explored. (1) A total of 108 patients with HR-NB were included in the final analysis. The overall infection rate was 92.6% (100/108), with the highest incidence of 71.3% observed during the first cycle. FN, bacterial infection, as well as fungal infection were common infectious complications in children with HR-NB during induction chemotherapy. (2) The overall hemorrhage rate was 24.1% (26/108), with the highest incidence of 14.8% also observed in the first cycle. Among the children with hemorrhage, there were 72% with bone marrow involved, while 65.0% of them had a high vanillylmandelic acid (VMA) value. And children with hemorrhage also exhibited neuron-specific enolase (NSE) ≥ 200 µg/L in 88.5% of cases and lactic dehydrogenase (LDH) ≥ 1000U/L in 73.1% of cases. (3) The incidence of CRAR rate was 100%, and 99.1% (107/108) patients experienced myelosuppression. The incidence of myelosuppression peaked in the third cycle, reaching up to 85.2%. Most children suffered severe myelosuppression existed with bone marrow metastases (76.3%), abnormal VMA (67.5%), and LDH ≥ 1000 U/L (60%). (4) Non-myelosuppressive adverse effects were observed in 75.9% children (82/108), with the highest incidence occurring in the third cycle at 42.6%. (5) Patients who experienced three types of complications had a lower median survival time (MST) of 54.4 months, a 3-year event-free survival (EFS) rate of (44.2 ± 10.7)%, and a 3-year overall survival (OS) rate of (75.8 ± 8.6)%, in comparison to those with only one or two complications, who had a higher MST of 59.5 months, a 3-year EFS rate of (73.5 ± 5.2)% (X2 = 10.457, P = 0.001), and a 3-year OS rate of (84.8 ± 4.1)% (X2 = 10.511, P = 0.001). Conclusion: The presence of bone marrow involved and increased VMA were high-risk factors for infection, while NSE ≥ 200 µg/L and LDH ≥ 1000 U/L were high-risk factors for hemorrhage. For those children who had experienced severe myelosuppression, the presence of bone marrow metastases, increased VMA, and LDH ≥ 1000 U/L were their risk factors. The presence of bone involvement was a high-risk factor for children to have non-myelosuppressive adverse effects. Complications that arise during induction chemotherapy could negatively impact the children’s prognosis and overall quality of life. What is Known: • The high-risk neuroblastoma (HR-NB) had a worse prognosis; there was a general international preference for high-intensity chemotherapeutic regimens in the induction phase to these children. What is New: • We analyzed the incidence and risk factors of complications during induction chemotherapy in children with HR-NB and tried to help clinicians predict such complications and adopt optimized therapeutic strategy.


  • Open Access

    A multicenter prospective study on the management of hepatoblastoma in children: a report from the Chinese Children’s Cancer Group

    by Meng-Jie Tang, Xiao-Li Ma, Xiang-Ling He, Wei-Hua Pan, Xiao-Hong Zhang, Sha-Yi Jiang, Ju Gao, Fu Li, Wei Yao, Song Gu, et al.

    Background: This study aimed to identify survival risk factors in Chinese children with hepatoblastoma (HB) and assess the effectiveness of the new treatment protocol proposed by the Chinese Children’s Cancer Group (CCCG) in 2016. Methods: A multicenter, prospective study that included 399 patients with HB from January 2015 to June 2020 was conducted. Patient demographics, treatment protocols, and other related information were collected. Cox regression models and Kaplan–Meier curve methods were used. Results: The 4-year event-free survival (EFS) and overall survival (OS) were 76.9 and 93.5%, respectively. The 4-year EFS rates for the very-low-risk, low-risk, intermediate-risk, and high-risk groups were 100%, 91.6%, 81.7%, and 51.0%, respectively. The 4-year OS was 100%, 97.3%, 94.4%, and 86.8%, respectively. Cox regression analysis found that age, tumor rupture (R +), and extrahepatic tumor extension (E +) were independent prognostic factors. A total of 299 patients had complete remission, and 19 relapsed. Patients with declining alpha-fetoprotein (AFP) > 75% after the first two cycles of neoadjuvant chemotherapy had a better EFS and OS than those ≤ 75%. Conclusions: The survival outcome of HB children has dramatically improved since the implementation of CCCG-HB-2016 therapy. Age ≥ 8 years, R + , and E + were independent risk factors for prognosis. Patients with a declining AFP > 75% after the first two cycles of neoadjuvant chemotherapy had better EFS and OS. Graphical


  • Businesses and Self-Employment

    by DeeDee M. Bennett Gayle, Xiaojun (Jenny) Yuan

    “When we look at the usage of AI and cloud, I think it is especially going to accelerate also not just us, but how our clients are going to go on their digital transformation. And I believe this crisis is only going to accelerate that as we go over the next few months.”

  • COVID-19 Mobile Applications

    by DeeDee M. Bennett Gayle, Xiaojun (Jenny) Yuan

    “Those who champion the use of smartphone tracking often ignore that the countries that successfully curbed their pandemics used smartphone apps alongside rigorous testing and aggressive phyiscal-distancing measures.”

  • Empowered or Left Behind

    by DeeDee M. Bennett Gayle, Xiaojun (Jenny) Yuan

    Focused on the United States, this book summarizes the secondary impacts of COVID-19 due to the increased use of technology. Establishing the global response of social distancing, mandates for non-essential business, and working from home, the book centers on the disparate guidance provided domestically at the state and local levels. Marginalized populations are highlighted to identify areas where technology facilitated access and reach or contributed to difficulties catapulted by digital literacy or digital access issues. To explain how people may have been empowered or left behind due to a new and unique reliance on technology, this book is structured based on the social determinants of health domains. Specifically, this book explains how technology was an umbrella domain that impacted every aspect of life during the pandemic including access, use, adoption, digital literacy, and digital equity, as well as privacy and security concerns. Given this book’s focus on the impacts to marginalized populations, there is a thread throughout the book related to the use of technology to perpetuate hate, discrimination, racism, and xenophobic behaviors that emerged as a twin pandemic during COVID-19. Part I explains the defining differences between primary and secondary impacts, as well as the unique guidelines adopted in each state. Part II of the book is focused on specific domains, where each chapter is dedicated to topics including economic stability through employment, education, healthcare, and the social/community context through access to services. Part III focuses on unique technological considerations related to COVID-19, such as mobile health-related apps and privacy or security issues that may have posed barriers to the adoption and use of technology. Finally, the book ends with a conclusion chapter, which explicitly explains the advantages and disadvantages of technology adoption during COVID-19. These exposed benefits and challenges will have implications for policies, disaster management practices, and interdisciplinary research.


  • Employment during COVID-19

    by DeeDee M. Bennett Gayle, Xiaojun (Jenny) Yuan

    “The crisis has uncovered the huge decent work deficits that still prevail in 2020 and shown how vulnerable millions of working people are when a crisis hits.”

  • Conclusion

    by DeeDee M. Bennett Gayle, Xiaojun (Jenny) Yuan

    “It had taken eight months and I was still no closer to seeing my first telemedicine patient. Yet once COVID hit, within two weeks, we had been able to turn this whole thing around, and I am doing virtual consulting and testing. It has been amazing to see how quickly healthcare overall has been able to adjust and change and do what is right for our patients in the middle of a crisis.”